International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
The serum immunoglobulin-free light chain (FLC) assay measures levels of free κ and λ
immunoglobulin light chains. There are three major indications for the FLC assay in the …
immunoglobulin light chains. There are three major indications for the FLC assay in the …
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for …
RA Kyle, BGM Durie, SV Rajkumar, O Landgren… - Leukemia, 2010 - nature.com
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21
463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of …
463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of …
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International …
Summary The International Myeloma Working Group consensus aimed to provide
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …
[HTML][HTML] Idecabtagene vicleucel in relapsed and refractory multiple myeloma
NC Munshi, LD Anderson Jr, N Shah… - … England Journal of …, 2021 - Mass Medical Soc
Background Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation
antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity …
antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity …
[HTML][HTML] Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective
M Tomblyn, T Chiller, H Einsele, R Gress… - Bone marrow …, 2009 - nature.com
Guidelines for preventing infectious complications among hematopoietic cell transplant
recipients: a global perspective | Bone Marrow Transplantation Skip to main content Thank you …
recipients: a global perspective | Bone Marrow Transplantation Skip to main content Thank you …
[HTML][HTML] Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo… - … England Journal of …, 2015 - Mass Medical Soc
Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling
lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with …
lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with …
[HTML][HTML] Cilta-cel or standard care in lenalidomide-refractory multiple myeloma
Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–
directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or …
directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or …
Tumor regression in cancer patients by very low doses of a T cell–engaging antibody
R Bargou, E Leo, G Zugmaier, M Klinger, M Goebeler… - Science, 2008 - science.org
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we
report on the clinical activity of a bispecific antibody construct called blinatumomab, which …
report on the clinical activity of a bispecific antibody construct called blinatumomab, which …
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
E Hoster, M Dreyling, W Klapper… - Blood, The Journal …, 2008 - ashpublications.org
There is no generally established prognostic index for patients with mantle cell lymphoma
(MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma …
(MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma …
[PDF][PDF] Targeted therapy with the T-cell–engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic …
MS Topp, P Kufer, N Gökbuget… - Journal of clinical …, 2011 - researchgate.net
Purpose Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a
member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In …
member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In …